BDBM372976 US10597366, Compound 15::US9896418, Compound 15

SMILES O[C@H]1c2c(CC1(F)F)c(Oc1cc(F)cc(c1)C#N)ccc2S(=O)(=O)C(F)F

InChI Key InChIKey=MXUSGDMIHGLCNC-HNNXBMFYSA-N

Data  2 IC50  6 EC50

PDB links: 1 PDB ID matches this monomer.

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 372976   

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372976(US10597366, Compound 15 | US9896418, Compound 15)
Affinity DataEC50:  13nMAssay Description:Four hours later, serial dilutions of 10× compound stocks were made in growth medium from 500×DMSO stocks, and 20 μL of those 10× stocks were ad...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372976(US10597366, Compound 15 | US9896418, Compound 15)
Affinity DataEC50:  13nMAssay Description:About 7500 of 786-0 cells in 180 μL of growth medium were seeded into each well of a 96 well plate with white clear bottom on the first day (07-...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

Curated by ChEMBL
LigandPNGBDBM372976(US10597366, Compound 15 | US9896418, Compound 15)
Affinity DataEC50:  233nMAssay Description:Antagonist activity at HIF-2alpha in human 786-O cells assessed as free plasma adjusted EC50 for reduction in VEGFA concentration after 24 hrs by ELI...More data for this Ligand-Target Pair
TargetVascular endothelial growth factor A(Human)
Peloton Therapeutics

US Patent
LigandPNGBDBM372976(US10597366, Compound 15 | US9896418, Compound 15)
Affinity DataEC50:  13nMAssay Description:VEGF: Four hours later, serial dilutions of 10x compound stocks were made in growth medium from 500xDMSO stocks, and 20 uL of those 10x stocks were a...More data for this Ligand-Target Pair
In DepthDetails US Patent

TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

Curated by ChEMBL
LigandPNGBDBM372976(US10597366, Compound 15 | US9896418, Compound 15)
Affinity DataEC50:  6nMAssay Description:Antagonist activity at HIF-2alpha in human 786-O cells co-expressing HIF responsive element after 24 hrs by ONE-Glo luciferase reporter gene assayMore data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

Curated by ChEMBL
LigandPNGBDBM372976(US10597366, Compound 15 | US9896418, Compound 15)
Affinity DataEC50:  14nMAssay Description:Antagonist activity at HIF-2alpha in human 786-O cells assessed as reduction in VEGFA concentration after 24 hrs by ELISAMore data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

Curated by ChEMBL
LigandPNGBDBM372976(US10597366, Compound 15 | US9896418, Compound 15)
Affinity DataIC50:  8nMAssay Description:HIF-2a: The total assay volume was about 100 uL in the following configuration: 2 uL compound in 100% DMSO, 88 uL buffer with protein and probe and 1...More data for this Ligand-Target Pair
TargetEndothelial PAS domain-containing protein 1(Human)
Peloton Therapeutics

Curated by ChEMBL
LigandPNGBDBM372976(US10597366, Compound 15 | US9896418, Compound 15)
Affinity DataIC50: <5nMAssay Description:Binding affinity to His-tagged HIF-2alpha PAS-B domain (unknown origin) after 2 hrs by scintillation proximity assayMore data for this Ligand-Target Pair